Although dual MEK1/2 and MET pathway inhibition had strong preclinical rationale in KRASMT CRC [20], the clinical efficacy was limited and does not support combined binimetinib/crizotinib in unselected, heavily pre-treated RASMT advanced CRC patients. The gene discussed is MAP2K1; the disease is colorectal carcinoma.